Jasper Therapeutics shares surge 10.33% intraday on positive Briquilimab data in Chronic Spontaneous Urticaria studies.

Jasper Therapeutics surged 10.33% intraday trading following the release of updated positive data from briquilimab studies in chronic spontaneous urticaria and the appointment of Jeet Mahal as CEO. The company highlighted promising results from its ETESIAN asthma trial and BEACON study investigation, alongside strategic leadership changes to drive clinical growth. Recent insider stock purchases and investor webinars further underscored confidence in the pipeline, aligning with the sharp intraday rally. These developments reinforced investor optimism about briquilimab’s therapeutic potential and operational restructuring, positioning the stock for near-term momentum.